FIELD: medicine.
SUBSTANCE: following is proposed: a method of intranasal administration of R4K2 KQLLPIVNKQSC peptide for the treatment of a respiratory viral infection caused by respiratory syncytial virus or influenza virus, where R is arginine; K is lysine; Q is glutamine, L is leucine, P is proline, I is isoleucine, V is valine, N is asparagine, S is serine, C is cysteine.
EFFECT: cationic branched R4K2 KQLLPIVNKQSC peptide blocks the entry of the virus into the cell both by binding to the cellular receptor nucleolin and by binding to ligands (F protein) on the surface of RSV.
1 cl, 13 dwg, 6 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS | 2021 |
|
RU2746362C1 |
| METHOD FOR PREVENTING AND TREATING BRONCHIAL ASTHMA, COMPLICATING RESPIRATORY VIRAL INFECTIONS AND OTHER RESPIRATORY INFLAMMATORY DISEASES | 2012 |
|
RU2526146C2 |
| PEPTIDE-BASED COMPOSITION SUPPRESSING REPLICATION OF INFLUENZA A VIRUS | 2018 |
|
RU2695336C1 |
| RESPIRATORY SYNCYTIAL VIRUS STRAIN RSV/NOVOSIBIRSK/66H1/2018 FOR USE IN THE DIAGNOSIS OF RESPIRATORY SYNCYTIAL VIRAL INFECTION AND THE STUDY OF THE EFFECTIVENESS OF ANTIVIRAL DRUGS IN VITRO | 2020 |
|
RU2746280C1 |
| APPLICATION OF COMPOSITION CONSISTING OF CATIONIC LTP PEPTIDE AND MOLECULES OF RNA AGAINST RESPIRATORY VIRUSES | 2015 |
|
RU2609857C1 |
| METHOD FOR PRODUCING PROPHYLACTIC ANTIVIRAL COMPOSITION BASED ON EPIGALLOCATECHIN-3-GALLATE (EGCG) | 2021 |
|
RU2771898C1 |
| TEST SYSTEM FOR DIAGNOSTICS OF AGENTS OF ACUTE RESPIRATORY VIRAL INFECTIONS | 2019 |
|
RU2733379C1 |
| MONOCLONAL ANTIBODIES SPECIFIC TO VARIOUS STRAINS OF RESPIRATORY SYNCYTIAL VIRUS | 2018 |
|
RU2713340C1 |
| F-PROTEIN OF RESPIRATORY SYNCYTIAL VIRUS AND ITS USE | 2007 |
|
RU2464316C2 |
| MELANINE ANTIVIRAL AGENT | 2011 |
|
RU2480227C2 |
